Overview

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Status:
Completed

Trial end date:
2020-01-27

Target enrollment:

Participant gender:

Summary

The purpose of the phase 1, GTO-003 clinical study is to determine the safety and pharmacokinetics of a single dose of a new drug called GC4711 when given as an oral capsule. This study will compare capsules of GC4711 when given orally to a similar drug, GC4419, or GC4711 when either is given as an intravenous infusion.

Phase:

Phase 1

Details

Lead Sponsor:

Galera Therapeutics, Inc.

Collaborators:

INC Research Australia Pty Ltd
Nucleus Network Ltd
Projections Research
Pyxant, Labs Inc.

Treatments:

Avasopasem manganese
Superoxide Dismutase